Early research (Phase 1)Study completedNCT01233895What this trial is testingStudy of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple MyelomaWho this might be right forMultiple Myeloma Sanofi 26
Testing effectiveness (Phase 2)Ended earlyNCT02753595What this trial is testingStudy of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)Who this might be right forMetastatic Breast Cancer Eisai Inc. 25
Not applicableStudy completedNCT00462475What this trial is testingEffect of 5 Years of GH Replacement on AtherosclerosisWho this might be right forHypopituitarismPituitary TumorsGrowth Hormone Deficiency Federico II University 20
Testing effectiveness (Phase 2)Study completedNCT00867334What this trial is testingNew Individualized Therapy Trial for Metastatic Colorectal CancerWho this might be right forColorectal NeoplasmColorectal Cancer Inova Health Care Services 10
Not applicableStudy completedNCT05905939What this trial is testingHER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in RussiaWho this might be right forBreast Cancer AstraZeneca 774
Early research (Phase 1)Ended earlyNCT01748812What this trial is testingCinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)Who this might be right forOsteomalacia National Institute of Dental and Craniofacial Research (NIDCR) 1
Testing effectiveness (Phase 2)Study completedNCT01565083What this trial is testingAssess Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in Participants With Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast CancerWho this might be right forBreast Cancer Hoffmann-La Roche 213
Testing effectiveness (Phase 2)Ended earlyNCT01394211What this trial is testingNeo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast CancerWho this might be right forEstrogen Receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Negative Carcinoma of BreastMale Breast Cancer+4 more University of Arizona 2
Not applicableStudy completedNCT06411093What this trial is testingEfficacy and Safety of Kinesiology Tape Wrapping for Paronychia Induced by Epidermal Growth Factor Receptor InhibitorsWho this might be right forParonychiaEpidermal Growth Factor Receptor Inhibitor Chang Gung Memorial Hospital 24
Testing effectiveness (Phase 2)UnknownNCT05111444What this trial is testingCamrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaWho this might be right forGastric NeoplasmsGastroesophageal Junction Adenocarcinoma Fudan University 65
Testing effectiveness (Phase 2)WithdrawnNCT05191004What this trial is testingStudy of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBCWho this might be right forAdvanced Breast CancerMetastatic Breast CancerBreast Cancer+5 more Nuvation Bio Inc.
Not applicableStudy completedNCT07342686What this trial is testingHypothalamic-Stratified Nursing Pathway for Pediatric CraniopharyngiomaWho this might be right forCraniopharyngiomaGrowth Hormone Deficiency (GHD) West China Hospital 500
Early research (Phase 1)Study completedNCT04204473What this trial is testingTY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive MutationWho this might be right forNSCLC TYK Medicines, Inc 105
Large-scale testing (Phase 3)Not Yet RecruitingNCT07818070What this trial is testingA Trial of ONO-4578 Versus Placebo in Combination With Nivolumab and Chemotherapy in Participants With Gastric Cancer, Esophagogastric Junction Cancer, or Esophageal AdenocarcinomaWho this might be right forGastric CancerEsophagogastric Junction CancerEsophageal Adenocarcinoma Ono Pharmaceutical Co., Ltd. 600
Testing effectiveness (Phase 2)Study completedNCT00004865What this trial is testingCetuximab Plus Cisplatin in Treating Patients With Metastatic or Recurrent Cancer of the Head and Neck That Has Not Responded to Cisplatin ChemotherapyWho this might be right forHead and Neck Cancer Jonsson Comprehensive Cancer Center
Early research (Phase 1)Study completedNCT01482377What this trial is testingRO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell OriginWho this might be right forNeoplasms Hoffmann-La Roche 145
Not applicableStudy completedNCT02623257What this trial is testingEGFR Mutations on ctDNA in Patients With Advanced NSCLCWho this might be right forNon-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic First People's Hospital of Hangzhou 1,055
Testing effectiveness (Phase 2)Study completedNCT01378962What this trial is testingTarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TRIGGER)Who this might be right forNon-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche 50
Testing effectiveness (Phase 2)Study completedNCT05549505What this trial is testingA Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to SurgeryWho this might be right forBreast Cancer Arvinas Inc. 152
Early research (Phase 1)Study completedNCT01445405What this trial is testingRadiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck CancerWho this might be right forCarcinoma, SquamousHead and Neck CancerOral Cancer+2 more National Cancer Institute (NCI) 3